Education
About Us
Working with TipRanks
Follow Us
Kyowa Kirin Co Ltd (JP:4151)
:4151
Top Page
Kyowa Kirin Co
(OTC:4151)
74Outperform
Kyowa Kirin Co (4151) vs. S&P 500 (SPY)
Market Cap
$1.09T
Dividend Yield2.55%
Average Volume (3M)1.31M
Price to Earnings (P/E)18.4
Beta (1Y)0.38
Revenue Growth12.06%
EPS Growth-25.28%
CountryJP
Employees5,669
SectorHealthcare
Sector Strength69
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)7.86
Shares Outstanding525,634,500
10 Day Avg. Volume1,502,940
30 Day Avg. Volume1,309,010
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,522.99Price Target Upside14.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Kyowa Kirin Co Business Overview & Revenue Model
Company DescriptionKyowa Kirin Co., Ltd. is a Japan-based global specialty pharmaceutical company focused on discovering, developing, and delivering innovative medicines. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on the research and development of novel therapeutics in the areas of oncology, nephrology, immunology, and the central nervous system. Kyowa Kirin's core products include a portfolio of proprietary drugs and biologics designed to address unmet medical needs across these therapeutic areas.
How the Company Makes MoneyKyowa Kirin Co. generates revenue through the sale of its pharmaceutical products, which are developed internally or through partnerships. The company's key revenue streams include the commercialization of its proprietary drugs in global markets, earning income from product sales and licensing agreements. Additionally, Kyowa Kirin collaborates with other pharmaceutical companies and research institutions, engaging in joint ventures and co-development agreements that contribute to its earnings. The company also invests in ongoing research and development to expand its pipeline of drug candidates, ensuring a steady flow of innovative products to maintain and grow its market presence.
Kyowa Kirin Co Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 495.56B | 442.23B | 398.37B | 352.25B | 318.35B | Gross Profit |
| 362.95B | 331.03B | 311.46B | 264.40B | 237.91B | EBIT |
| 91.87B | 95.84B | 68.66B | 61.17B | 52.56B | EBITDA |
| 116.65B | 118.53B | 82.81B | 79.86B | 74.71B | Net Income Common Stockholders |
| 59.87B | 81.19B | 53.57B | 52.35B | 47.03B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 246.39B | 405.01B | 339.72B | 336.52B | 287.65B | Total Assets |
| 1.07T | 1.03T | 939.88B | 921.87B | 801.29B | Total Debt |
| 0.00 | 0.00 | 23.28B | 22.54B | 18.28B | Net Debt |
| -244.68B | -403.08B | -315.92B | -312.55B | -268.74B | Total Liabilities |
| 216.55B | 189.52B | 177.06B | 184.71B | 102.89B | Stockholders Equity |
| 850.81B | 836.42B | 762.83B | 737.16B | 698.40B |
| Cash Flow | Free Cash Flow | |||
| 41.85B | 82.70B | 20.01B | 66.78B | 4.27B | Operating Cash Flow |
| 67.88B | 115.55B | 48.67B | 86.55B | 39.50B | Investing Cash Flow |
| -142.39B | -20.38B | -17.18B | -11.36B | 252.56B | Financing Cash Flow |
| -84.70B | -32.53B | -29.03B | -28.45B | -26.00B |
Kyowa Kirin Co Technical Analysis
Neutral
2199.00
Price Trends
2149.92
Positive
2243.46
Negative
2552.38
Negative
Market Momentum
11.74
Negative
54.66
Neutral
69.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4151, the sentiment is Neutral. The current price of 2199 is above the 20-day moving average (MA) of 2156.05, above the 50-day MA of 2149.92, and below the 200-day MA of 2552.38, indicating a neutral trend. The MACD of 11.74 indicates Negative momentum. The RSI at 54.66 is Neutral, neither overbought nor oversold. The STOCH value of 69.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4151.
Kyowa Kirin Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $10.34T | 26.70 | 22.80% | 1.33% | 17.96% | 25.65% | |
74 Outperform | $1.09T | 18.44 | 6.95% | 2.55% | 12.06% | -25.28% | |
68 Neutral | $6.78T | 32.40 | 2.87% | 4.04% | 9.83% | 15.49% | |
65 Neutral | $1.15T | 19.69 | 6.83% | 3.89% | 5.63% | 30.61% | |
62 Neutral | $2.29T | 49.09 | 3.22% | 4.85% | 19.25% | 294.48% | |
51 Neutral | $5.31B | 3.39 | -40.42% | 2.90% | 18.11% | 2.25% | |
39 Underperform | $270.16B | ― | -68.59% | ― | 12.84% | -1.34% |
* Healthcare Sector Average
Performance Comparison
JP:4151
Kyowa Kirin Co
2,196.50
-392.97
-15.18%
JP:4506
Sumitomo Dainippon Pharma Co
680.00
281.00
70.43%
JP:4503
Astellas Pharma
1,381.50
-63.43
-4.39%
JP:4519
Chugai Pharmaceutical Co
8,274.00
3,259.63
65.01%
JP:4523
Eisai Co
4,073.00
-2,218.06
-35.26%
JP:4502
Takeda Pharmaceutical Co
4,275.00
304.95
7.68%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.